Tenaya Therapeutics Financials
| TNYA Stock | USD 3.57 0.28 8.51% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Debt Equity Ratio | 0.0325 | 0.031 |
|
| |||||
| Current Ratio | 4.66 | 4.9084 |
|
|
The essential information of the day-to-day investment outlook for Tenaya Therapeutics includes many different criteria found on its balance sheet. An individual investor should monitor Tenaya Therapeutics' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Tenaya Therapeutics.
Net Income |
|
Tenaya | Select Account or Indicator |
Understanding current and past Tenaya Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Tenaya Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Tenaya Therapeutics' assets may result in an increase in income on the income statement.
Please note, the presentation of Tenaya Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Tenaya Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Tenaya Therapeutics' management manipulating its earnings.
Tenaya Therapeutics Stock Summary
Tenaya Therapeutics competes with Bicycle Therapeutics, IGM Biosciences, Monte Rosa, Stoke Therapeutics, and Biomea Fusion. Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. The company was incorporated in 2016 and is headquartered in South San Francisco, California. Tenaya Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 135 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US87990A1060 |
| CUSIP | 87990A106 |
| Location | California; U.S.A |
| Business Address | 171 Oyster Point |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.tenayatherapeutics.com |
| Phone | 650 825 6990 |
| Currency | USD - US Dollar |
Tenaya Therapeutics Key Financial Ratios
| Return On Equity | -0.84 | ||||
| EBITDA | (122.51 M) | ||||
| Net Income | (124.08 M) | ||||
| Cash Per Share | 4.37 X | ||||
| Debt To Equity | 0.07 % |
Tenaya Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Tenaya Therapeutics's current stock value. Our valuation model uses many indicators to compare Tenaya Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Tenaya Therapeutics competition to find correlations between indicators driving Tenaya Therapeutics's intrinsic value. More Info.Tenaya Therapeutics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At present, Tenaya Therapeutics' Return On Equity is projected to slightly decrease based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Tenaya Therapeutics' earnings, one of the primary drivers of an investment's value.Tenaya Therapeutics Systematic Risk
Tenaya Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Tenaya Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was ten with a total number of output elements of fifty-one. The Beta measures systematic risk based on how returns on Tenaya Therapeutics correlated with the market. If Beta is less than 0 Tenaya Therapeutics generally moves in the opposite direction as compared to the market. If Tenaya Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Tenaya Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Tenaya Therapeutics is generally in the same direction as the market. If Beta > 1 Tenaya Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Tenaya Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Tenaya Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Tenaya Therapeutics growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Tenaya Therapeutics November 30, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Tenaya Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Tenaya Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Tenaya Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Tenaya Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Tenaya Therapeutics's daily price indicators and compare them against related drivers.
| Downside Deviation | 4.96 | |||
| Information Ratio | 0.0534 | |||
| Maximum Drawdown | 38.23 | |||
| Value At Risk | (6.88) | |||
| Potential Upside | 12.11 |
Complementary Tools for Tenaya Stock analysis
When running Tenaya Therapeutics' price analysis, check to measure Tenaya Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tenaya Therapeutics is operating at the current time. Most of Tenaya Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tenaya Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tenaya Therapeutics' price. Additionally, you may evaluate how the addition of Tenaya Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like |